Advertisement


Toni K. Choueiri, MD, on RCC: Treatment With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib

2021 Genitourinary Cancers Symposium

Advertisement

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carcinoma, lenvatinib plus pembrolizumab improved outcomes vs sunitinib. Lenvatinib plus everolimus also improved progression-free survival and overall survival rates vs sunitinib (Abstract 269).



Related Videos

Bladder Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer Highlights From the 2021 Genitourinary Cancers Symposium

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses key abstracts discussed at this year’s meeting on bladder cancer and offers her views on the latest trends and...

Bladder Cancer
Immunotherapy

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Enfortumab Vedotin-ejfv vs Chemotherapy

Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, discusses phase III results from the EV-301 trial, which showed that enfortumab vedotin is the first therapy to de...

Prostate Cancer

Felix Y. Feng, MD, on Prostate Cancer: Choosing Patients Who May Benefit From Apalutamide

Felix Y. Feng, MD, of the University of California, San Francisco, discusses study findings showing that molecular determinants may help clinicians select patients with nonme...

Bladder Cancer
Immunotherapy

Monika Joshi, MD, on Urothelial Cancer of the Bladder: Durvalumab and Radiotherapy for Localized Disease

Monika Joshi, MD, of Penn State Hershey Cancer Institute, discusses phase II results from the DUART study, which explored the efficacy of concurrent durvalumab, a checkpoint ...

Kidney Cancer

Elizabeth R. Plimack, MD, on Renal Cell Cancer Highlights From the 2021 Genitourinary Cancers Symposium

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses key abstracts discussed at this year’s meeting on renal cell carcinoma and offers her views on the latest tren...

Advertisement

Advertisement



Advertisement